Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016

Description: Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016

Summary

‘Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN)
- The report reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cervical Intraepithelial Neoplasia (CIN) therapeutics and enlists all their major and minor projects
- The report assesses Cervical Intraepithelial Neoplasia (CIN) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline
therapeutics
- Devise corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Cervical Intraepithelial Neoplasia (CIN) Overview
Therapeutics Development
Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview
Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Investigation by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance
Clinical Stage Products
Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies
Cervical Intraepithelial Neoplasia (CIN) - Products under Investigation by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
CEL-SCI Corporation
Genexine, Inc.
Helix BioPharma Corp.
Inovio Pharmaceuticals, Inc.
PDS Biotechnology Corporation
Transgene SA
Vaccibody AS
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles

BLSPGAC-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

GLBL-101c - Drug Profile
Product Description
Mechanism of Action
R&D Progress

GX-188E - Drug Profile
Product Description
Mechanism of Action
R&D Progress

interferon alpha-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Leukocyte Interleukin - Drug Profile
Product Description
Mechanism of Action
R&D Progress

PDS-0101A - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VB-1016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cervical Intraepithelial Neoplasia (CIN) - Recent Pipeline Updates
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
Featured News & Press Releases
Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress
Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology
Feb 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune Cancer Immunotherapy Platform in a Phase 1 Clinical Trial
Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill

Research and Markets
Target Cells In Phase I Study

May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer

Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application

Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines

Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2016

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corporation, H1 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine, Inc., H1 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Helix BioPharma Corp., H1 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corporation, H1 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H1 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Cervical Intraepithelial Neoplasia (CIN) Therapeutics - Recent Pipeline Updates, H1 2016
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H1 2016
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2016
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3774206/](http://www.researchandmarkets.com/reports/3774206/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3774206/
Office Code: SCH3G821

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Ms [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World